Articles tagged with Cancer Medication
Researchers at Georgetown University Medical Center found that combining tamoxifen with hydroxychloroquine reverses resistance to the breast cancer drug in mice. The study's findings provide a promising new treatment option for women with advanced estrogen receptor-positive breast cancer.
Researchers at Case Western Reserve University found that existing cancer treatment bortezomib increases levels of the vascular-protective gene KLF2, preventing blood clot formation. This discovery has potential implications for managing thrombosis in patients with predispositions to clot formation.
A class of leukemia drug has been found to stimulate immunity against multiple cancer types. Inhibiting the p110δ enzyme helps boost the body's immune system to kill tumor cells.
A new class of tumor-targeting agents can seek out and find dozens of solid tumors, even illuminating brain cancer stem cells that resist current treatments. The agents deliver two types of payloads directly to cancer cells, resulting in direct imaging or treatment.
Mayo Clinic researchers have identified a new form of cancer caused by a chromosomal chimera, characterized by a biphenotypic sinonasal sarcoma. The rare tumor typically begins in the nose and may require disfiguring surgery to treat.
Researchers found an association between decreased carbohydrate intake and reduced breast cancer recurrence among women whose tumor tissue is positive for the IGF-1 receptor. The study suggests that personalized diets based on molecular characteristics of primary tumors may be possible, but further research is needed.
Scientists have identified a new biomarker called Neuromedin U (NmU) that may help predict and overcome resistance to newer anti-cancer drugs for HER2 positive cancers. The discovery could lead to more effective treatment strategies and improved patient outcomes.
A comprehensive clinical trial found that SPECT/CT imaging detected significantly more sentinel lymph node involvement with various types of cancers, including melanoma, breast carcinoma, and pelvic malignancies. This improved imaging technique has the potential to alter surgical planning and improve patient outcomes.
A new therapy that combines chemotherapy with radiounclide treatment has shown promising results in slowing or stopping the progression of neuroendocrine cancer. In a study of 68 patients, the therapy resulted in stabilization or regression of the disease in 70% of cases, leading to improved patient survival rates.
Researchers have discovered that over-expression of Cripto-1 makes lung cancer cells resistant to erlotinib, a widely used targeted therapy. Blocking Cripto-1 signaling restored sensitivity to the drug in cell lines and animals, suggesting a potential reversal mechanism.
Recent Medicare data release reveals high payments to a few doctors, but experts caution that this does not necessarily indicate poor care. The data only shows the amount of care provided, not its appropriateness, and may be influenced by factors such as specialty and geography.
Healthcare experts examine potential cost savings in maternal mortality reduction, adolescent cancer treatment, and biosimilar medication use. Studies reveal the importance of long-term financing plans and access to follow-up care for improved outcomes.
Scientists at EPFL introduce a novel biosensor molecule that can quickly measure drug concentration in patients' systems using a digital camera. The method is simple, low-cost, and can be used by patients themselves.
Researchers found that early palliative support services significantly reduced depression and feelings of overwhelm among family caregivers, improving overall quality of life. The study suggests that timely intervention can better equip caregivers to cope with the demands of caring for patients with advanced cancer.
Researchers at Mayo Clinic have demonstrated a potential delivery vehicle for brain cancer chemotherapy drugs, enabling the transport of eight different molecules across the blood-brain barrier. The breakthrough method mimics a normal physiological process and could aid in evaluation of new drugs for brain cancer treatment.
Researchers develop new computational method to design novel protein nanostructures, including cage-like proteins with symmetrical architectures. These structures may be used to deliver cancer drugs directly to tumor cells, sparing healthy cells.
The American Society of Clinical Oncology recognizes MD Anderson leaders Gabriel Hortobagyi, Waun Ki Hong, and John Mendelsohn for their significant contributions to cancer research. Mendelsohn is known for his discovery of the monoclonal antibody Erbitux, while Hong has made groundbreaking advances in treating head and neck cancers.
A study found that approximately 25% of children with acute lymphocytic leukemia (ALL) are missing too many doses of essential maintenance medication, which minimizes the risk of relapse. Nonadherence triples relapse risk, with African Americans and Asians being more prone to non-adherence than non-Hispanic whites.
The DREAM project has successfully mined genomic data to predict breast cancer cell line responses to drugs, achieving 78% accuracy in identifying sensitive versus resistant cell lines. The study also identified molecular markers that can be tested against large collections of human samples.
A phase 1b immunotherapy trial combining nivolumab and ipilimumab has shown high one-year and two-year overall survival rates of 94% and 88%, respectively, in advanced melanoma patients. The treatment regimen has demonstrated long-lasting benefits for these patients.
Research confirms BRCA2 gene mutations increase lung cancer risk by 1.8 times in smokers and double the risk for some individuals. The study also identified associations with CHEK2 and TP63 genes, highlighting potential targets for early screening and treatment.
A Phase III clinical trial found that enzalutamide significantly reduced the risk of prostate cancer progression by 81 percent and improved overall survival by 29 percent. The treatment also helped prevent cancer spread to bones and delayed chemotherapy needs.
A preclinical study of Rice University's quadrapeutics technology found that it can detect and kill cancer cells instantly, without harming surrounding normal organs. The technology uses a combination of existing clinical treatments and mechanical events triggered by nano-explosions to target cancer cells.
Researchers used gene expression arrays to analyze biopsies from ICON7 patients and found that patients with proliferative and mesenchymal subtypes responded best to bevacizumab. This subtype analysis may help identify patients who will benefit from the treatment, potentially reducing unnecessary toxicity.
A new trial found that giving chemotherapy immediately to men with newly diagnosed, hormone-sensitive prostate cancer can extend their survival by more than a year. The study showed significant benefits in both overall and high-extent disease populations.
Researchers at Mount Sinai present promising findings on innovative treatments for recurrent ovarian cancer, molecular profiling of bile duct and gallbladder cancers, and adjuvant therapy for melanoma. The studies demonstrate encouraging results for patients with these rare and often fatal diseases.
Researchers have found that crizotinib produces significant responses in patients with intermediate and high MET amplification, resulting in a 60-67% overall objective response rate. The drug showed early activity against MET-dependent cells in preclinical laboratory studies.
OMP-54F28, a Wnt inhibitor targeting cancer stem cells, has shown promising results in a Phase I clinical trial. The drug was generally well-tolerated and resulted in stable disease for over six months in several patients with advanced solid tumors.
A University of Colorado Cancer Center study found NTRK1 mutations in over 1% of non-small cell lung cancer patients. The study also developed a test for rapid detection of NTRK1 oncogenes, marking a new frontier in lung cancer treatment.
Researchers presented promising results from four clinical trials featuring new targeted drugs for advanced ovarian, lung and thyroid cancers, as well as chronic lymphocytic leukemia. These treatments showed potential to slow disease progression and improve survival rates for patients with relapses or treatment resistance.
Researchers report promising results from a phase I study on MPDL3280A, an investigational drug for treating advanced bladder cancer. The trial showed improved response rates among patients with PD-L1-positive tumors, with 7% achieving complete responses.
A phase 3 study found that ibrutinib significantly lengthened progression-free survival as a second-line therapy for CLL, with 86% of patients on ibrutinib experiencing durable responses. Ibrutinib also showed superior results compared to ofatumumab in terms of overall survival and partial response rates.
The American Society for Clinical Oncology has released new clinical guidelines for cancer-related fatigue, developed in collaboration with Moffitt Cancer Center. The guidelines recommend regular screening and treatment of fatigue in cancer patients after treatment, as well as addressing other contributing factors such as depression, p...
Jackson Laboratory Assistant Professors Jennifer Trowbridge and Chengkai Dai have received federal research grants to investigate acute myeloid leukemia and metformin's anti-cancer effects. They aim to elucidate specific problems in key areas of cancer research.
Researchers found that discontinuing statins in patients with advanced illnesses resulted in improved overall quality of life and lower costs without increased deaths. Patients who stopped taking statins appeared to live slightly longer, with median survival times of 229 days compared to 190 days for those continuing the drug.
A new study found that prostate cancer patients who underwent external beam radiation therapy were 70% more likely to develop rectal cancer and 40% more likely for bladder cancer. Survivors should be aware of symptoms such as pelvic pain, difficulty urinating, or blood in stool to monitor for potential secondary cancers.
The investigational agent DMOT4039A, a combination of chemotherapeutic agent and antibody, showed initial evidence of anti-cancer activity in a phase I clinical trial for pancreatic and ovarian cancers. The drug targets mesothelin-rich cancer cells, reducing the risk of off-target effects.
Researchers at the University of California, San Diego School of Medicine have identified two gene mutations that cause uveal melanoma, a type of eye cancer. They also found that an existing FDA-approved drug can slow tumor growth in experiments with mice.
Researchers at the University of Montreal have discovered a novel mechanism of drug resistance in leukemia and other cancers, which is driven by overactivity of the GLI1 gene. The team has identified drugs that can inhibit this gene's activity, potentially switching cancer cells back into sensitivity to existing chemotherapy.
Researchers have developed nanoscale structures called 'nanodaisies' that can deliver multiple anti-cancer drugs to cancer cells. These daisy-shaped structures show promise in treating lung, leukemia, breast, prostate, liver, ovarian and brain cancers.
Researchers have created an innovative 3D test system that allows them to simulate human body functions, enabling the development of more effective cancer treatments. The artificial lung model, no bigger than a sugar cube, can be used to analyze treatment resistance and metastasis formation, potentially leading to personalized medicine.
Cancer cells utilize a protein called Aiolos, which allows them to acquire blood cell characteristics and spread throughout the body. Researchers have discovered how this mechanism works, offering hope for future treatments.
Scientists have identified two genes, MLF2 and RPL39, that may affect the most lethal type of breast cancer. Suppressing these genes can reduce tumor formation and metastasis by interfering with blood vessel formation and recruitment.
Researchers at Yale Cancer Center presented findings from the 50th Annual Meeting of ASCO, highlighting the effectiveness of nivolumab and ipilimumab in treating advanced melanoma. Additionally, studies showed that lifestyle changes such as healthy eating and regular exercise can decrease biomarkers related to breast cancer recurrence ...
A phase I study found that alisertib inhibited aurora A kinase, a target for aggressive lymphoma treatment, in about one-third of patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia. The oral drug showed manageable side effects, paving the way for advanced trials.
A new centre, The Oxford Centre for Drug Delivery Devices (OxCD3), will be established to exploit engineering approaches to improve the therapeutic outcomes of drug-based cancer treatments. The centre aims to use stimulus-responsive nanocarriers and medical devices to enhance drug delivery into tumours.
Researchers at UC Berkeley have discovered the mechanism by which Taxol interferes with microtubule polymerization, preventing cell division in cancer cells. This finding could lead to the development of better anticancer drugs and improvements to existing treatments.
Researchers have successfully blocked autophagy in a range of aggressive cancers, including glioblastoma, melanoma, and myeloma, using hydroxychloroquine. The study shows that combining autophagy inhibitors with other cancer therapies can be safe and effective for patients with very sick cancers.
Researchers from VTT Technical Research Centre of Finland discover a new anticancer compound, Cent-1, that kills cancer cells through a similar mechanism to Rigosertib. This breakthrough uses computer-assisted screening and cell-based assays to accelerate drug discovery and potentially lower development costs.
Researchers used computer simulations to identify most effective drugs for brain cancer, considering genomic signatures and predicted sensitivities. The approach may help personalize therapies for cancer patients, selectively testing effective drugs while reducing exposure to toxic ones.
A team of researchers created a database called K-Map that allows scientists to reposition existing drugs to treat various types of cancer. The database enables the evaluation of rational drugs and drug combinations, leading to new potential treatments such as bosutinib for non-small cell lung cancer.
Researchers at Penn State have identified a pine bark substance, leelamine, that can simultaneously target multiple protein pathways in melanoma cells, shutting down their survival communication and leading to cell death. This unique approach may address the issue of resistance to current melanoma drugs.
Chemists at Scripps Research Institute have determined the correct structure of TIC10, a promising anticancer compound approved by FDA for clinical trials. The correct structure differs from an earlier published version and describes a molecule with potent anticancer effects in animals.
The Gordon Sondland and Katherine Durant Foundation has donated $1 million to the Oregon Health & Science University's Knight Cancer Institute to establish an annual research conference, drawing top thought leaders in cancer treatment. The conference aims to accelerate breakthroughs in early detection and treatment.
Cancer research calls on institutions to increase Hispanic patient enrollment, highlighting health disparities and underrepresentation in clinical trials. The study emphasizes the need for adequate representation to ensure effective treatment and reduce disparities.
Scientists used neutron scattering techniques to study mAb clustering, revealing extended clusters in high-viscosity solutions. The insights could help design devices for delivering biopharmaceuticals at high concentrations.
The University of Louisville has received a three-year, $5.5 million grant from the Leona M. and Harry B. Helmsley Charitable Trust to develop new treatments and vaccines for various forms of cancer. Researchers will focus on plant-based pharmaceuticals and vaccines for cervical and colon cancer.
Dr. Neal Meropol, Chief of Hematology and Oncology at Case Western Reserve University, is honored as an ASCO Fellow for his exceptional volunteer service and dedication to cancer care. He has served on the ASCO Board of Directors and various committees, contributing to the organization's mission to improve cancer care.
Researchers are testing whether therapy incorporating advanced genomic technology will provide better outcomes than current treatments for women with an aggressive form of breast cancer. The trial uses targeted DNA sequencing to identify specific treatment choices that improve survival rates.
Researchers developed a new technology that can generate visible light deep within the body, activating drugs and destroying tumors. This approach could greatly expand photodynamic therapy's effectiveness, offering fewer side effects and precise targeting of cancer cells.